Treatment of Hypertension in Patients with Coronary Artery Disease. A Case-Based Summary of the 2015 AHA/ACC/ASH Scientific Statement

Writing Committee

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

The 2015 American Heart Association/American College of Cardiology/American Society of Hypertension Scientific Statement "Treatment of Hypertension in Patients with Coronary Artery Disease" is summarized in the context of a clinical case. The Statement deals with target blood pressures, and the optimal agents for the treatment of hypertension in patients with stable angina, in acute coronary syndromes, and in patients with ischemic heart failure. In all cases, the recommended blood pressure target is <140/90 mm Hg, but <130/80 mm Hg may be appropriate, especially in those with a history of a previous myocardial infarction or stroke, or at high risk for developing either. These numbers may need to be revised after the publication of the SPRINT data. Appropriate management should include beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and in the case of heart failure, aldosterone antagonists. Thiazide or thiazide-like (chlorthalidone) diuretics and calcium channel blockers can be used for the management of hypertension, but the evidence for improved outcomes compared with other agents in hypertension with coronary artery disease is meager. Loop diuretics should be reserved for patients with New York Heart Association Class III and IV heart failure or with a glomerular filtration rate of <30 mL/min.

Original languageEnglish (US)
Pages (from-to)372-378
Number of pages7
JournalAmerican Journal of Medicine
Volume129
Issue number4
DOIs
StatePublished - Apr 1 2016

Fingerprint

Coronary Artery Disease
Hypertension
Thiazides
Heart Failure
Chlorthalidone
Blood Pressure
Mineralocorticoid Receptor Antagonists
Sodium Potassium Chloride Symporter Inhibitors
Stable Angina
Angiotensin Receptor Antagonists
Calcium Channel Blockers
Therapeutics
Acute Coronary Syndrome
Glomerular Filtration Rate
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Publications
Stroke
Myocardial Infarction

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Treatment of Hypertension in Patients with Coronary Artery Disease. A Case-Based Summary of the 2015 AHA/ACC/ASH Scientific Statement. / Writing Committee.

In: American Journal of Medicine, Vol. 129, No. 4, 01.04.2016, p. 372-378.

Research output: Contribution to journalReview article

@article{d50904d9f4a94e64a4af96f4be494c6b,
title = "Treatment of Hypertension in Patients with Coronary Artery Disease. A Case-Based Summary of the 2015 AHA/ACC/ASH Scientific Statement",
abstract = "The 2015 American Heart Association/American College of Cardiology/American Society of Hypertension Scientific Statement {"}Treatment of Hypertension in Patients with Coronary Artery Disease{"} is summarized in the context of a clinical case. The Statement deals with target blood pressures, and the optimal agents for the treatment of hypertension in patients with stable angina, in acute coronary syndromes, and in patients with ischemic heart failure. In all cases, the recommended blood pressure target is <140/90 mm Hg, but <130/80 mm Hg may be appropriate, especially in those with a history of a previous myocardial infarction or stroke, or at high risk for developing either. These numbers may need to be revised after the publication of the SPRINT data. Appropriate management should include beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and in the case of heart failure, aldosterone antagonists. Thiazide or thiazide-like (chlorthalidone) diuretics and calcium channel blockers can be used for the management of hypertension, but the evidence for improved outcomes compared with other agents in hypertension with coronary artery disease is meager. Loop diuretics should be reserved for patients with New York Heart Association Class III and IV heart failure or with a glomerular filtration rate of <30 mL/min.",
author = "{Writing Committee} and Clive Rosendorff and Lackland, {Daniel T.} and Matthew Allison and Aronow, {Wilbert S.} and Black, {Henry R.} and Blumenthal, {Roger S.} and Cannon, {Christopher P.} and {De Lemos}, {James A.} and Elliott, {William J.} and Laura Findeiss and Gersh, {Bernard J.} and Gore, {Joel M.} and Daniel Levy and Long, {Janet B.} and O'Connor, {Christopher M.} and O'Gara, {Patrick T.} and Olugbenga Ogedegbe and Suzanne Oparil and Laura Findeiss",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.amjmed.2015.10.045",
language = "English (US)",
volume = "129",
pages = "372--378",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Treatment of Hypertension in Patients with Coronary Artery Disease. A Case-Based Summary of the 2015 AHA/ACC/ASH Scientific Statement

AU - Writing Committee

AU - Rosendorff, Clive

AU - Lackland, Daniel T.

AU - Allison, Matthew

AU - Aronow, Wilbert S.

AU - Black, Henry R.

AU - Blumenthal, Roger S.

AU - Cannon, Christopher P.

AU - De Lemos, James A.

AU - Elliott, William J.

AU - Findeiss, Laura

AU - Gersh, Bernard J.

AU - Gore, Joel M.

AU - Levy, Daniel

AU - Long, Janet B.

AU - O'Connor, Christopher M.

AU - O'Gara, Patrick T.

AU - Ogedegbe, Olugbenga

AU - Oparil, Suzanne

AU - Findeiss, Laura

PY - 2016/4/1

Y1 - 2016/4/1

N2 - The 2015 American Heart Association/American College of Cardiology/American Society of Hypertension Scientific Statement "Treatment of Hypertension in Patients with Coronary Artery Disease" is summarized in the context of a clinical case. The Statement deals with target blood pressures, and the optimal agents for the treatment of hypertension in patients with stable angina, in acute coronary syndromes, and in patients with ischemic heart failure. In all cases, the recommended blood pressure target is <140/90 mm Hg, but <130/80 mm Hg may be appropriate, especially in those with a history of a previous myocardial infarction or stroke, or at high risk for developing either. These numbers may need to be revised after the publication of the SPRINT data. Appropriate management should include beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and in the case of heart failure, aldosterone antagonists. Thiazide or thiazide-like (chlorthalidone) diuretics and calcium channel blockers can be used for the management of hypertension, but the evidence for improved outcomes compared with other agents in hypertension with coronary artery disease is meager. Loop diuretics should be reserved for patients with New York Heart Association Class III and IV heart failure or with a glomerular filtration rate of <30 mL/min.

AB - The 2015 American Heart Association/American College of Cardiology/American Society of Hypertension Scientific Statement "Treatment of Hypertension in Patients with Coronary Artery Disease" is summarized in the context of a clinical case. The Statement deals with target blood pressures, and the optimal agents for the treatment of hypertension in patients with stable angina, in acute coronary syndromes, and in patients with ischemic heart failure. In all cases, the recommended blood pressure target is <140/90 mm Hg, but <130/80 mm Hg may be appropriate, especially in those with a history of a previous myocardial infarction or stroke, or at high risk for developing either. These numbers may need to be revised after the publication of the SPRINT data. Appropriate management should include beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and in the case of heart failure, aldosterone antagonists. Thiazide or thiazide-like (chlorthalidone) diuretics and calcium channel blockers can be used for the management of hypertension, but the evidence for improved outcomes compared with other agents in hypertension with coronary artery disease is meager. Loop diuretics should be reserved for patients with New York Heart Association Class III and IV heart failure or with a glomerular filtration rate of <30 mL/min.

UR - http://www.scopus.com/inward/record.url?scp=84961956403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961956403&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2015.10.045

DO - 10.1016/j.amjmed.2015.10.045

M3 - Review article

VL - 129

SP - 372

EP - 378

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 4

ER -